<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461434</url>
  </required_header>
  <id_info>
    <org_study_id>GRAF-01-SCCT</org_study_id>
    <nct_id>NCT01461434</nct_id>
  </id_info>
  <brief_title>Graz Study on the Risk of Atrial Fibrillation</brief_title>
  <acronym>GRAF</acronym>
  <official_title>Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common clinical arrhythmia. AF is associated with
      increased risk for stroke due to blood clots formed in the fibrillating atria. Some patient
      characteristics increase the likelyhood of AF and at the same time the risk of stroke when AF
      has developed. To reduce the risk of stroke, anticoagulation therapy is recommended in
      patients with AF and risk factors (such as high blood pressure, diabetes, vessel disease).
      However, occasional (paroxysmal) AF may occur without symptoms and remain undetected, leaving
      patients at risk.

      Aim of the prospective randomized study is to compare two management strategies for patients
      at increased risk for AF but without a known history of AF. Patients are seen regularly
      (monthly, then quarterly) for follow-up (incl. ECG recording and blood sample). One group of
      patients additionally receives a subcutaneous implantation of a loop recorder for continuous
      rhythm monitoring, while the control group remains on standard follow-up. Observation period
      is one year (optional extension for 3 years). The time to first diagnosis of AF is compared
      between groups, blood samples are analyzed for potential biomarkers of AF.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first diagnosis of atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to change in therapy based on the diagnosis of atrial fibrillation</measure>
    <time_frame>Baseline (0 months), 1,2,3,4,5,6,9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP serum level associated with occurrence of atrial fibrillation</measure>
    <time_frame>Baseline (0 months), 1,2,3,4,5,6,9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <condition>Chronic Heart Failure</condition>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>loop recorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be implanted with a subcutaneous loop recorder and have regular follow-ups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>regular follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive regular follow-ups with standard ECG</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Reveal XT implantable loop recorder</intervention_name>
    <description>subcutaneous implantation</description>
    <arm_group_label>loop recorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CHA2DS2-VASc risk score &gt;= 4*

          -  18 years or older

        Exclusion Criteria:

          -  known history of atrial fibrillation

          -  implanted rhythm device

          -  pre-existing indication for oral anticoagulation

        (*)CHA2DS2-VASc: C - chronic heart failure (1 point); H - hypertension (1 point); A - age
        &gt;= 75 years (2 points); D - diabetes (1 point); S - stroke (2 points); V - vascular disease
        (1 point); A - age &gt;=65 and &lt; 75 years (1 point); Sc - sex category (female) (1 point) ;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LKH/Uniklinikum - Klinische Abteilung f√ºr Kardiologie</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>December 20, 2015</last_update_submitted>
  <last_update_submitted_qc>December 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Frank R Heinzel, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor Frank R. Heinzel, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>biomarkers</keyword>
  <keyword>stroke prevention</keyword>
  <keyword>implantable loop recorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

